{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:29:48Z","timestamp":1785162588993,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.ijrobp.2014.01.017","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T06:03:06Z","timestamp":1395554586000},"page":"1041-1047","source":"Crossref","is-referenced-by-count":109,"title":["Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"88","clinical-trial-number":[{"clinical-trial-number":"nct01319942","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shang-Wen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ching","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-An","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chun","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Fong","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2014.01.017_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An update","volume":"35","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib3","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/cncr.21811","article-title":"Radiation therapy for hepatocellular carcinoma: From palliation to cure","volume":"106","author":"Hawkins","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0360-3016(00)00462-4","article-title":"Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma","volume":"47","author":"Cheng","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0360-3016(03)00434-6","article-title":"Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma","volume":"57","author":"Yamada","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib6","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2174\/1381612023393026","article-title":"BAY 43-9006: Preclinical data","volume":"8","author":"Wilhelm","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/1471-2407-12-485","article-title":"Sorafenib modulates the radiosensitivity of hepatocellular carcinoma cells in\u00a0vitro in a schedule-dependent manner","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.semradonc.2011.05.009","article-title":"Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies?","volume":"21","author":"Dawson","year":"2011","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2005.12.031","article-title":"Radiation-induced liver disease in three-dimensional conformal radiotherapy for primary liver carcinoma: The risk factor and hepatic radiation tolerance","volume":"65","author":"Liang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib14","unstructured":"National Cancer Institute. Common terminology criteria for adverse events version 4.0 (CTCAE). 2009. Available at http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed May, 2009."},{"key":"10.1016\/j.ijrobp.2014.01.017_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib17","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1038\/sj.onc.1209706","article-title":"Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K\/Akt\/NFkappaB signal transduction pathway","volume":"25","author":"Cheng","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib18","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1158\/1078-0432.CCR-05-2721","article-title":"Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma","volume":"12","author":"Chung","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib19","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","article-title":"Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation","volume":"67","author":"Plastaras","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib20","doi-asserted-by":"crossref","first-page":"e65726","DOI":"10.1371\/journal.pone.0065726","article-title":"Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma","volume":"8","author":"Wild","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib21","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2012.07.033","article-title":"Phase I study of sorafenib and stereotactic radiotherapy for advanced hepatocellular carcinoma","volume":"84","author":"Dawson","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib","volume":"104","author":"Llanos","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0360-3016(02)02864-X","article-title":"Dose-response relationship in local radiotherapy for hepatocellular carcinoma","volume":"54","author":"Park","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/cncr.21043","article-title":"Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma","volume":"103","author":"Kim","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2014.01.017_bib25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.coc.0000239147.60196.11","article-title":"Thee-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable","volume":"29","author":"Kim","year":"2006","journal-title":"Am J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301614000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301614000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T19:24:17Z","timestamp":1538767457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301614000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0360301614000753"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.017","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}